BACKGROUND & AIMS: Mutational inactivation of adenomatous polyposis coli (APC) is an early event in colorectal cancer (CRC) progression that affects the stability and increases the activity of β-catenin, a mediator of Wnt signaling. Progression of CRC also involves inactivation of signaling via transforming growth factor β and bone morphogenetic protein (BMP), which are tumor suppressors. However, the interactions between these pathways are not clear. We investigated the effects of loss of the transcription factor Smad4 on levels of β-catenin messenger RNA (mRNA) and Wnt signaling. METHODS: We used microarray analysis to associate levels of Smad4 and β-catenin mRNA in colorectal tumor samples from 250 patients. We performed oligonucleotide-mediated knockdown of Smad4 in human embryonic kidney (HEK293T) and in HCT116 colon cancer cells and transgenically expressed Smad4 in SW480 colon cancer cells. We analyzed adenomas from (APC(Δ1638/+)) and (APC(Δ1638/+)) × (K19Cre(ERT2)Smad4(lox/lox)) mice by using laser capture microdissection. RESULTS: In human CRC samples, reduced levels of Smad4 correlated with increased levels of β-catenin mRNA. In Smad4-depleted cell lines, levels of β-catenin mRNA and Wnt signaling increased. Inhibition of BMP or depletion of Smad4 in HEK293T cells increased binding of RNA polymerase II to the β-catenin gene. Expression of Smad4 in SW480 cells reduced Wnt signaling and levels of β-catenin mRNA. In mice with heterozygous disruption of Apc(APC(Δ1638/+)), Smad4-deficient intestinal adenomas had increased levels of β-catenin mRNA and expression of Wnt target genes compared with adenomas from APC(Δ1638/+) mice that expressed Smad4. CONCLUSIONS: Transcription of β-catenin is inhibited by BMP signaling to Smad4. These findings provide important information about the interaction among transforming growth factor β, BMP, and Wnt signaling pathways in progression of CRC. Copyright Â
BACKGROUND & AIMS: Mutational inactivation of adenomatous polyposis coli (APC) is an early event in colorectal cancer (CRC) progression that affects the stability and increases the activity of β-catenin, a mediator of Wnt signaling. Progression of CRC also involves inactivation of signaling via transforming growth factor β and bone morphogenetic protein (BMP), which are tumor suppressors. However, the interactions between these pathways are not clear. We investigated the effects of loss of the transcription factor Smad4 on levels of β-catenin messenger RNA (mRNA) and Wnt signaling. METHODS: We used microarray analysis to associate levels of Smad4 and β-catenin mRNA in colorectal tumor samples from 250 patients. We performed oligonucleotide-mediated knockdown of Smad4 in humanembryonic kidney (HEK293T) and in HCT116colon cancer cells and transgenically expressed Smad4 in SW480colon cancer cells. We analyzed adenomas from (APC(Δ1638/+)) and (APC(Δ1638/+)) × (K19Cre(ERT2)Smad4(lox/lox)) mice by using laser capture microdissection. RESULTS: In human CRC samples, reduced levels of Smad4 correlated with increased levels of β-catenin mRNA. In Smad4-depleted cell lines, levels of β-catenin mRNA and Wnt signaling increased. Inhibition of BMP or depletion of Smad4 in HEK293T cells increased binding of RNA polymerase II to the β-catenin gene. Expression of Smad4 in SW480 cells reduced Wnt signaling and levels of β-catenin mRNA. In mice with heterozygous disruption of Apc(APC(Δ1638/+)), Smad4-deficient intestinal adenomas had increased levels of β-catenin mRNA and expression of Wnt target genes compared with adenomas from APC(Δ1638/+) mice that expressed Smad4. CONCLUSIONS: Transcription of β-catenin is inhibited by BMP signaling to Smad4. These findings provide important information about the interaction among transforming growth factor β, BMP, and Wnt signaling pathways in progression of CRC. Copyright Â
Authors: Hafid Alazzouzi; Pia Alhopuro; Reijo Salovaara; Heli Sammalkorpi; Heikki Järvinen; Jukka-Pekka Mecklin; Akeseli Hemminki; Simo Schwartz; Lauri A Aaltonen; Diego Arango Journal: Clin Cancer Res Date: 2005-04-01 Impact factor: 12.531
Authors: Martin Isaksson-Mettävainio; Richard Palmqvist; Johan Forssell; Roger Stenling; Ake Oberg Journal: Anticancer Res Date: 2006 Jan-Feb Impact factor: 2.480
Authors: M Miyaki; T Iijima; M Konishi; K Sakai; A Ishii; M Yasuno; T Hishima; M Koike; N Shitara; T Iwama; J Utsunomiya; T Kuroki; T Mori Journal: Oncogene Date: 1999-05-20 Impact factor: 9.867
Authors: Stayce E Beck; Barbara H Jung; Antonio Fiorino; Jessica Gomez; Eunice Del Rosario; Betty L Cabrera; Sherry C Huang; Jimmy Y C Chow; John M Carethers Journal: Am J Physiol Gastrointest Liver Physiol Date: 2006-07 Impact factor: 4.052
Authors: T C He; A B Sparks; C Rago; H Hermeking; L Zawel; L T da Costa; P J Morin; B Vogelstein; K W Kinzler Journal: Science Date: 1998-09-04 Impact factor: 47.728
Authors: Xi C He; Jiwang Zhang; Wei-Gang Tong; Ossama Tawfik; Jason Ross; David H Scoville; Qiang Tian; Xin Zeng; Xi He; Leanne M Wiedemann; Yuji Mishina; Linheng Li Journal: Nat Genet Date: 2004-09-19 Impact factor: 38.330
Authors: J R Howe; M G Sayed; A F Ahmed; J Ringold; J Larsen-Haidle; A Merg; F A Mitros; C A Vaccaro; G M Petersen; F M Giardiello; S T Tinley; L A Aaltonen; H T Lynch Journal: J Med Genet Date: 2004-07 Impact factor: 6.318
Authors: W M Grady; L L Myeroff; S E Swinler; A Rajput; S Thiagalingam; J D Lutterbaugh; A Neumann; M G Brattain; J Chang; S J Kim; K W Kinzler; B Vogelstein; J K Willson; S Markowitz Journal: Cancer Res Date: 1999-01-15 Impact factor: 12.701
Authors: Joana F S Pereira; Nikhil T Awatade; Cláudia A Loureiro; Paulo Matos; Margarida D Amaral; Peter Jordan Journal: Cell Mol Life Sci Date: 2016-05-04 Impact factor: 9.261
Authors: Jun Won Park; Seok Hoon Jang; Dong Min Park; Na Jung Lim; Chuxia Deng; Dae Yong Kim; Jeffrey E Green; Hark Kyun Kim Journal: Mol Cancer Res Date: 2014-04-30 Impact factor: 5.852
Authors: Ansu O Perekatt; Pooja P Shah; Shannon Cheung; Nidhi Jariwala; Alex Wu; Vishal Gandhi; Namit Kumar; Qiang Feng; Neeket Patel; Lei Chen; Shilpy Joshi; Anbo Zhou; M Mark Taketo; Jinchuan Xing; Eileen White; Nan Gao; Michael L Gatza; Michael P Verzi Journal: Cancer Res Date: 2018-07-09 Impact factor: 12.701
Authors: Angela Criscimanna; Li-Juan Duan; Julie A Rhodes; Volker Fendrich; Emily Wickline; Douglas J Hartman; Satdarshan P S Monga; Michael T Lotze; George K Gittes; Guo-Hua Fong; Farzad Esni Journal: Cancer Res Date: 2013-06-07 Impact factor: 12.701